XML 25 R48.htm IDEA: XBRL DOCUMENT
v3.19.3

Collaborative Arrangements and Licensing Agreements, Pfizer (Details) - Akcea [Member] - USD ($) shares in Millions, $ in Millions | 1 Months Ended | 3 Months Ended
--- | --- | ---
Oct. 31, 2019 | Dec. 31, 2019 | Mar. 31, 2019
Collaborative Arrangement and Licensing Agreement [Abstract] |  |  |
Sublicense fee paid for license of drug |  |  | $ 75
Additional shares of Akcea stock received (in shares) |  |  | 2.8
Pfizer [Member] | Forecast [Member] |  |  |
Collaborative Arrangement and Licensing Agreement [Abstract] |  |  |
Sublicense fee paid for license of drug |  | $ 125 |
Additional shares of Akcea stock received (in shares) |  | 6.9 |
Pfizer [Member] | Subsequent Event [Member] |  |  |
Collaborative Arrangement and Licensing Agreement [Abstract] |  |  |
Upfront license fee to be received | $ 250 |  |
Maximum amount of payments receivable for development, regulatory and sales milestones | $ 1,300 |  |
Royalty percentage received on net sales of drug | 20.00% |  |

X
- References No definition available. + Details
Name: | ions_CollaborativeArrangementAndLicensingAgreementAbstract
Namespace Prefix: | ions_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The maximum amount of payments receivable for development, regulatory and sales milestones under the collaboration agreement. + References No definition available. + Details
Name: | ions_MaximumAmountOfPaymentsReceivableForDevelopmentRegulatoryAndSalesMilestones
Namespace Prefix: | ions_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The number of shares received from the subsidiary during the period. + References No definition available. + Details
Name: | ions_ReceiptOfSharesInSubsidiary
Namespace Prefix: | ions_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Royalty percentage received on the net sales of a drug by a collaboration partner under the collaboration agreement. + References No definition available. + Details
Name: | ions_RoyaltyPercentageReceivedOnNetSalesOfDrug
Namespace Prefix: | ions_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of the sublicense fee paid in common stock. + References No definition available. + Details
Name: | ions_SublicenseFeePaidForLicenseOfDrug
Namespace Prefix: | ions_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of upfront license fees expected to be received under the collaboration agreement. + References No definition available. + Details
Name: | ions_UpfrontLicenseFeeToBeReceived
Namespace Prefix: | ions_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Details
Name: | srt_ConsolidatedEntitiesAxis=ions_AkceaTherapeuticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementScenarioAxis=srt_ScenarioForecastMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |